OOIR: Observatory of International Research

Papers

(The TQCC of Melanoma Research is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Temozolomide monotherapy versus combination therapies in melanoma: a meta-analysis of efficacy and safety	21
Genetic concordance in melanoma: insights from primary tumors and their matched distant metastases	17
A comparison of myeloid-derived suppressor cell populations in patients with ulcerated vs non-ulcerated melanoma receiving immune checkpoint blockade	17
Eruptive melanocytic nevi in a patient with amelanotic melanoma: a paraneoplastic phenomenon?	16
Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors	16
Polymorphisms in toll-like receptor 3 and 4 genes as prognostic and outcome biomarkers in melanoma patients	12
Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice	12
Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma	11
Efficacy of topical diphencyprone for melanoma in-transit metastases: a systematic review and meta-analysis	10
Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel	10
Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma	10
Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors	10
Genetic causal relationship between gut microbiota and cutaneous melanoma: a two-sample Mendelian randomization study	10
Simultaneous melanomas in the setting of multiple primary melanomas	10
Management of metastatic bone disease of melanoma	10
Targeting beta-adrenergic receptor pathways in melanoma: how stress modulates oncogenic immunity	10
Surgery of small bowel melanoma metastases in the era of efficient medical therapies: a retrospective cohort study	9
The importance of mitosis ≥2 in selecting patients with T1 cutaneous melanomas for sentinel lymph node biopsy	9
Immune-related adverse events are associated with therapeutic efficacy of immunotherapy in patients with melanoma brain metastases	9
Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging	9
High-resolution RNA-sequencing reveals TRIM33::CSDE1 gene fusion in metastasizing vulvar melanoma	8
ATF3 regulates CDC42 transcription and influences cytoskeleton remodeling, thus inhibiting the proliferation, migration and invasion of malignant skin melanoma cells	8
Clinicopathological demographics of malignant melanomas of the vulva and vagina in Japan	8
Aseptic cystitis induced by nivolumab and ipilimumab combination for metastatic melanoma	8
Telomere length is associated with increased risk of cutaneous melanoma: a Mendelian randomization study	8

Ponatinib-induced eruptive nevi and melanocytic proliferation	8
The inhibitory role of microRNA-141-3p in human cutaneous melanoma growth and metastasis through the fibroblast growth factor 13-mediated mitogen-activated protein kinase axis	8
Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma	8
Prognosis of CDKN2A germline mutation in patients with familial melanoma: a systematic review and meta-analysis	8
Recurrent hemophagocytic lymphohistiocytosis in advanced melanoma treated with two different BRAF/MEK-inhibitor regimens	7
Anorectal melanoma: systematic review of the current literature of an aggressive type of melanoma	7
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting	7
Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients	7
Regorafenib in patients with pretreated advanced melanoma: a single-center case series	7
Causal relationship between sex hormones and cutaneous melanoma: a two-sample Mendelian randomized study	7
Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1	7
Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread	7
The association between dermatologist density and melanoma prognosis using melanoma mortality-incidence ratio	7
Management of cardiac metastases of melanoma in the era of immunotherapy: a case series	6
MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance	6
Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients	6
Melanotransferrin is efficiently sorted on the surface of exosomes secreted by melanoma cells	6
Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?	6
The human and animals’ malignant melanoma: comparative tumor models and the role of microbiome in dogs and humans	6
Updates on the diagnosis, current and future therapeutic options in Merkel-cell carcinoma	6
Development and validation of prognostic nomogram in pediatric melanoma: a population-based study	6
Clinical features, molecular characteristics and surgical management of primary penile mucosal melanoma based on the European Association of Urology Penile Cancer Guidelines	6
Study of clinical characteristics and risk factors for amelanotic/hypomelanotic melanoma in an Australian cohort	6
Melanoma in the head and neck region: the value of preoperative imaging in melanoma stage I–II	5
Macrophage inhibitory cytokine-1 produced by melanoma cells contributes to melanoma tumor growth and metastasis in vivo by enhancing tumor vascularization	5
BRCA1-associated protein 1 c.368delG mutation leads to the development of multiple BAPomas and cutaneous melanomas: a novel pathogenic variant in BRCA1-associated protein tumor predisposition syndrome	5
Expression of the cancer stem cell marker OCT4 is associated with worse prognosis and survival in cutaneous melanoma	5
Immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies, in a patient with melanoma treated with BRAF/MEK inhibitors	5
Hypoxic transcriptomes predict survival and tumor-infiltrating immune cell composition in cutaneous melanoma	5
Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-li	5
Melanocytic neoplasms in neurofibromatosis type 1: a systematic review	5
LS-007 inhibits melanoma growth via inducing apoptosis and cell cycle arrest and regulating macrophage polarization	5
Nodular type predominance of head and neck cutaneous malignant melanoma in Asian populations leads to poor outcome and low survival	5
Complete response of brainstem metastasis in BRAF-mutated melanoma without stereotactic radiosurgery after initiation of encorafenib and binimetinib	4
COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: a case report	4
Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study	4
Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies	4
Acute appendicitis secondary to desmoplastic melanoma metastasis in immune-checkpoint inhibitors era	4
Vitamin D insufficiency and serum levels related to the incidence and stage of cutaneous melanoma: a systematic review and meta-analysis	4
Effectiveness and safety of talimogene laherparepvec and granulocyte-macrophage colony-stimulating factor for metastatic melanoma: a systematic review and network meta-analysis of randomized controlle	4
Assessment of lipid and pigment content in suspicious melanocytic lesions to improve melanoma detection	4
Rate of response to immune checkpoint inhibitor therapy in patients with conjunctival melanoma	4
DNA methylation of GITR, OX40, 4-1BB, CD27, and CD40 correlates with BAP1 aberrancy and prognosis in uveal melanoma	4
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma	3
Seborrheic keratosis-like melanoma: a diagnostic challenge	3
Combination of radiotherapy and targeted therapy for melanoma brain metastases: a systematic review	3
The potential of using artificial intelligence to improve skin cancer diagnoses in Hawai‘i’s multiethnic population	3
Vitiligo-like hypopigmentation induced by dabrafenib-trametinib: a potential marker for clinical response	3
Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma	3
The role of wide local excision of a primary lesion in cutaneous malignant melanoma: a retrospective analysis of its usefulness in local and general control of disease	3

Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice	3
The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma	3
Efficacy of radiotherapy combined with immune checkpoint inhibitors in patients with melanoma: a systemic review and meta-analysis	3
The number needed to biopsy for cutaneous melanoma in academic dermatology clinics	3
Melanoma risk during immunomodulating treatment	3
Melanomas and mast cells: an ambiguous relationship	3
The effect of COVID-19 on early melanoma detection	3
The influence of metastatic patterns and tumor load on therapeutic efficacy of immunotherapy in patients with metastatic melanoma as determined by quantitative PET-parameters using [18F]-fluorodeoxygl	3
Nivolumab-induced immune-mediated acute gastritis in a melanoma patient	3
The impact of statins on melanoma survival: a systematic review and meta-analysis	3
Ultraviolet A radiation exposure and melanoma: a review	3
Tocilizumab in the treatment of steroid refractory immune-related hepatotoxicity: a case series and review of the literature	3
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma: Erratum	3
Comprehensive clinical imaging, histopathological analysis and liquid biopsy-based surveillance of human uveal melanoma in a prolonged rabbit xenograft model	3
The death rate for melanoma remained unchanged in the USA during the coronavirus disease 2019 pandemic	3
Do cortisol and psychological distress levels impact the effectiveness of immunotherapy in patients with metastasized melanoma? A pilot study	3
Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series	3
Brain metastases during follow-up of patients with resected cutaneous melanoma	3
Molecular profiling of primary uveal melanoma: results of a Polish cohort	3
Impact of gene expression profiling on diagnosis and survival after metastasis in patients with uveal melanoma	3
Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy	3
Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma	3
Nivolumab exposure in a hemodialysis patient with metastatic melanoma	3
Treatment outcomes following partial shave biopsy of atypical and malignant melanocytic tumors in pediatric patients	3